Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
239
-
Total 13F shares, excl. options
-
69,514,116
-
Shares change
-
+718,778
-
Total reported value, excl. options
-
$3,206,303,623
-
Value change
-
+$38,331,356
-
Put/Call ratio
-
120%
-
Number of buys
-
128
-
Number of sells
-
111
-
Price
-
$46.13
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2023
As of 30 Jun 2023 Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) had 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 69,514,116 shares of stock of the company.
Largest 10 holders included VANGUARD GROUP INC, RTW INVESTMENTS, LP, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, Clearbridge Investments, LLC, SANDS CAPITAL MANAGEMENT, LLC, STATE STREET CORP, ALKEON CAPITAL MANAGEMENT LLC, and FEDERATED HERMES, INC..
This table shows 239 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.